Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254891 · ClinicalTrials.gov registry record · Phase 3
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 828
- Enrollment target
NCT00254891 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 828 participants.
The verdict
NCT00254891, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 828 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Interventions
- DRUG Paclitaxel + Carboplatin
- DRUG PF-3512676 + Paclitaxel + Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 828 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254891
The ClinicalTrials.gov registry entry for NCT00254891 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 828 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel + Carboplatin is the first listed.
NCT00254891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254891 about?
NCT00254891 is a clinical study titled "Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer". To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
What is the current status of trial NCT00254891?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 828 participants. The study started on 2005-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00254891?
The interventions under investigation include: Paclitaxel + Carboplatin (DRUG), PF-3512676 + Paclitaxel + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00254891?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.